Table 2.
League table of NMA estimations.
| (A) Network meta-analysis comparisons for clinical effective rate | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CD | ||||||||||||||||||||||
| 0.16 (0.03,0.69) | CDDP | |||||||||||||||||||||
| 0.11 (0.04,0.26) | 0.66 (0.11,4.09) | CDDP+CD | ||||||||||||||||||||
| 0.33 (0.07,1.43) | 2.05 (0.24,17.82) | 3.11 (0.53,18.86) | CXC | |||||||||||||||||||
| 0.24 (0.15,0.36) | 1.45 (0.31,7.62) | 2.20 (0.82,6.73) | 0.71 (0.15,3.51) | CXC+CD | ||||||||||||||||||
| 0.41 (0.11,1.47) | 2.53 (0.36,19.87) | 3.85 (0.81,20.21) | 1.24 (0.17,9.20) | 1.73 (0.45,6.89) | DHHYK | |||||||||||||||||
| 0.31 (0.13,0.70) | 1.88 (0.35,11.58) | 2.85 (0.86,10.97) | 0.92 (0.17,5.29) | 1.29 (0.51,3.40) | 0.74 (0.16,3.50) | HXMMT+CD | ||||||||||||||||
| 0.31 (0.05,1.63) | 1.92 (0.18,19.29) | 2.92 (0.37,20.89) | 0.93 (0.09,9.07) | 1.32 (0.20,7.41) | 0.75 (0.08,6.25) | 1.01 (0.13,6.54) | MMDHP+CD | |||||||||||||||
| 0.23 (0.10,0.42) | 1.38 (0.26,7.58) | 2.09 (0.66,6.94) | 0.68 (0.13,3.50) | 0.95 (0.41,2.04) | 0.55 (0.12,2.24) | 0.74 (0.23,2.03) | 0.72 (0.11,5.00) | QG | ||||||||||||||
| 0.19 (0.08,0.42) | 1.15 (0.21,6.93) | 1.74 (0.50,6.53) | 0.56 (0.10,3.20) | 0.79 (0.30,2.00) | 0.45 (0.10,2.10) | 0.61 (0.18,1.94) | 0.60 (0.09,4.53) | 0.83 (0.29,2.54) | QG+CD | |||||||||||||
| 0.27 (0.09,0.77) | 1.66 (0.27,11.24) | 2.50 (0.66,11.20) | 0.81 (0.13,5.18) | 1.13 (0.38,3.66) | 0.65 (0.12,3.49) | 0.88 (0.23,3.39) | 0.86 (0.12,7.22) | 1.18 (0.37,4.59) | 1.44 (0.39,5.65) | SDMUC | ||||||||||||
| 0.21 (0.07,0.56) | 1.28 (0.21,8.48) | 1.95 (0.47,8.20) | 0.62 (0.10,3.91) | 0.88 (0.27,2.65) | 0.50 (0.09,2.59) | 0.68 (0.17,2.50) | 0.67 (0.09,5.43) | 0.93 (0.27,3.25) | 1.12 (0.28,4.22) | 0.77 (0.17,3.25) | SDMUC+CD | |||||||||||
| (B) Network meta-analysis comparisons for visual acuity | ||||||||||||||||||||||
| CD | ||||||||||||||||||||||
| -0.19 (-0.41,0.03) | CDDP | |||||||||||||||||||||
| -0.09 (-0.25,0.05) | 0.10 (-0.17,0.36) | CDDP+CD | ||||||||||||||||||||
| -0.46 (-0.68,-0.24) | -0.27 (-0.58,0.04) | -0.37 (-0.62,-0.10) | CXC+CD | |||||||||||||||||||
| -0.07 (-0.29,0.15) | 0.12 (-0.19,0.43) | 0.02 (-0.23,0.29) | 0.39 (0.08,0.70) | DHHYK | ||||||||||||||||||
| -0.11 (-0.24,0.02) | 0.08 (-0.17,0.33) | -0.02 (-0.21,0.18) | 0.35 (0.10,0.60) | -0.04 (-0.29,0.21) | QG+CD | |||||||||||||||||
| (C) Network meta-analysis comparisons for visual field gray value | ||||||||||||||||||||||
| CD | ||||||||||||||||||||||
| 1.29 (0.73,1.81) | CDDP | |||||||||||||||||||||
| 0.93 (0.67,1.19) | -0.36 (-0.93,0.27) | CDDP+CD | ||||||||||||||||||||
| 0.92 (0.75,1.08) | -0.37 (-0.91,0.21) | -0.02 (-0.32,0.29) | CXC+CD | |||||||||||||||||||
| 0.51 (-0.00,1.02) | -0.78 (-1.50,-0.01) | -0.42 (-1.00,0.15) | -0.41 (-0.95,0.13) | HXMMT+CD | ||||||||||||||||||
| 0.99 (0.63,1.35) | -0.30 (-0.92,0.37) | 0.06 (-0.39,0.50) | 0.07 (-0.33,0.47) | 0.48 (-0.15,1.11) | MMDHP+CD | |||||||||||||||||
| (D) Network meta-analysis comparisons for microaneurysm volume | ||||||||||||||||||||||
| CD | ||||||||||||||||||||||
| 3.05 (2.56,3.51) | CDDP+CD | |||||||||||||||||||||
| 3.52 (3.05,3.99) | 0.47 (-0.19,1.15) | CXC+CD | ||||||||||||||||||||
| 4.04 (3.14,4.95) | 0.99 (-0.01,2.03) | 0.53 (-0.49,1.54) | HXMMT+CD | |||||||||||||||||||
| 3.17 (2.66,3.65) | 0.12 (-0.56,0.81) | -0.35 (-1.05,0.33) | -0.87 (-1.92,0.14) | MMDHP+CD | ||||||||||||||||||
| (E) Network meta-analysis comparisons for hemorrhage area | ||||||||||||||||||||||
| CD | ||||||||||||||||||||||
| 0.80 (0.50,1.10) | CDDP | |||||||||||||||||||||
| 0.81 (0.69,0.96) | 0.01 (-0.31,0.35) | CDDP+CD | ||||||||||||||||||||
| 0.81 (0.73,0.90) | 0.01 (-0.30,0.32) | -0.01 (-0.17,0.15) | CXC+CD | |||||||||||||||||||
| 0.56 (0.38,0.74) | -0.24 (-0.59,0.11) | -0.25 (-0.50,-0.04) | -0.25 (-0.46,-0.05) | HXMMT+CD | ||||||||||||||||||
| 0.85 (0.73,0.99) | 0.05 (-0.27,0.38) | 0.04 (-0.16,0.22) | 0.05 (-0.11,0.20) | 0.29 (0.07,0.53) | MMDHP+CD | |||||||||||||||||
| 0.91 (0.76,1.05) | 0.10 (-0.23,0.44) | 0.09 (-0.12,0.28) | 0.10 (-0.07,0.26) | 0.35 (0.11,0.58) | 0.05 (-0.15,0.24) | SDMUC+CD | ||||||||||||||||
| (F) Network meta-analysis comparisons for macular thickness | ||||||||||||||||||||||
| CD | ||||||||||||||||||||||
| 68.87 (36.48,101.20) | CDDP+CD | |||||||||||||||||||||
| 70.76 (55.83,85.51) | 1.88 (-33.73,37.47) | CXC+CD | ||||||||||||||||||||
| 45.19 (-0.48,90.77) | -23.67 (-79.56,32.22) | -25.57 (-73.48,22.60) | HXMMT+CD | |||||||||||||||||||
| 52.16 (19.76,84.49) | -16.71 (-62.45,29.08) | -18.60 (-54.01,17.02) | 6.98 (-49.01,62.74) | MMDHP+CD | ||||||||||||||||||
| 22.01 (-23.93,67.98) | -46.85 (-102.96,9.49) | -48.75 (-97.01,-0.34) | -23.23 (-87.96,41.40) | -30.15 (-86.36,26.06) | QG | |||||||||||||||||
| 47.06 (14.64,79.50) | -21.85 (-67.65,24.15) | -23.69 (-59.28,12.00) | 1.85 (-54.22,57.84) | -5.09 (-50.87,40.55) | 25.04 (-31.22,81.28) | SDMUC+CD | ||||||||||||||||
The differences between the compared groups were deemed as significant when the 95% CrI of the OR did not contain 1.00 or the MD did not contain 0.00, which is marked as bold font. The data are the OR (95% CrI) of the column intervention compared to the row intervention, i.e., for the clinical effective rate, CD alone was significantly less effective than CDDP alone (OR 0.16, 95% CrI 0.03,0.69). CD, calcium dobesilate; CXC, Compound Xueshuantong Capsule; CDDP, Compound Danshen Dripping Pill; SDMUC, Shuangdan Mingmu Capsule; QG, Qiming Granule; HXMMT, Hexuemingmu Tablet; DHHYK, Danhong Huayu Koufuye; MMDHP, Mingmu Dihuang Pill.